VEGFA and neoplasm: While an analysis of tumor growth kinetics in patients receiving the anti-VEGF antibody bevacizumab suggested that it could accelerate disease progression after the end of treatment (Stein et al., 2008), such evidence does not exist for small molecule inhibitors of the VEGFR (Stein et al., 2012).